Clinical effect of hemopexin on treatment of patients with sepsis,inflammatory status,miR210 and IncRNA H19
OBJECTIVE To investigate the clinical benefit of hemopexin to sepsis patients and the effects on inflam-matory status,microribonucleic acid 210(miR210)and long-chain noncoding ribonucleic acid(IncRNA)H19.METHODS Totally 60 sepsis patients admitted to the Affiliated Hospital of Shandong Second Medical University from Oct.2021 to Oct.2022 were selected and divided into the control group with 30 cases and the experimental group with 30 cases by the randomized numerical table method.The control group was given conventional treat-ment,including early fluid resuscitation,assisted ventilation,oxygenation,maintenance of acid-base-electrolyte balance,nutritional support and anti-infection.The experimental group was given additional hemopexin injection.Both groups were treated continuously for 7 days,afterwards the laboratory indexes,inflammation and immune function-related indicators and one-month outcomes were analyzed.RESULTS Times for first bowel sounds and defecation in the test group[(2.03±0.27)d and(2.31±0.42)d,respectively]were earlier than those in the control group[(2.98±0.51)d and(4.01±0.78)d,P＜0.05,respectively];and the length of emergency inten-sive care unit(EICU)stay in the test group[(5.01±0.95)d]was shorter than that in the control group[(7.14±1.13)d](P＜0.05).After 7 days of treatment,the levels of alanine aminotransferase(ALT),creati-nine(CRE),cardiac troponin T(cTnT),lactate(Lac),miR210,high mobility group protein Bl(HMGB1),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),procalcitonin(PCT),white blood cells(WBC),inter-leukin-6(IL-6)in the test group were lower than those in the control group(P＜0.05).The levels of IncRNA H19,CD4+,CD3+,CD4+/CD8+B cells and NK cells were higher in the test group than those in the control group(P＜0.05);the acute physiology and assessment of chronic health conditions Ⅱ and sepsis-related organ failure assessment scores[(10.32±1.17)and(7.65±0.61)points]were lower in the test group than those in the control group[(14.98±1.56)and(12.67±2.25)points](P＜0.05).CONCLUSION After hemopexin treat-ment,the miR210 is down-regulated and IncRNA H19 is up-regulated,inflammatory response,immune function and organ function are significantly improved,and the symptoms are effectively controlled,which can shorten the length of EICU stay,improve the outcomes of the patients and bring great clinical benefits.
SepsisHemopexinClinical effectInflammatory stateMicroribonucleic acid 210Long-chain non-coding ribonucleic acid H19High mobility group protein B1
万方数据
维普
